Viral Vector And Plasmid DNA Manufacturing Market to Garner a Valuation of US$ 2,205.6 Million by 2027, at CAGR of 22.8%, Global Industry Analysis by Type, Diagnosis, Treatment, Size, Growth, Top Company Profile, Regional Revenue
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Request FREE Sample
Global Viral Vector and Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasma DNA, and Non-viral DNA Vectors), By Therapeutic Application (Cancer, Inherited Disorders, Infectious Diseases, and Others), By End Product (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 427.2 million in 2019, and is expected to exhibit a CAGR of 22.8% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
The increasing incidence of HIV is expected to offer growth opportunities to industry players operating in the global market. For instance, according to the Joint United Nations Program on HIV/AIDS in 2018, over 37.9 million people were diagnosed with HIV, whereas 24.5 million people across the globe received antiretroviral therapy till June 2019.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/962
Various research institutes are focusing on the development of viral vectors and plasmid DNA, which is expected to drive the market growth over the forecast period. For instance, in October 2019, researchers at the National Institutes of Health developed a novel viral vector, which is a vehicle to deliver gene therapy to patients suffering from sickle cell anemia.
Browse 34 Market Data Tables and 33 Figures spread through 201 Pages and in-depth TOC on Viral Vector and Plasmid DNA Manufacturing Market- Global Forecast to 2027, by Product Type (Viral Vector (Retroviral Vectors, Adenoviral Vectors, Lentiviral Vectors, Adeno-associated Viral Vectors, and Others), Plasmid DNA, and Non-viral DNA Vectors), By Therapeutic Application (Cancer, Inherited Disorders, Infectious Diseases, and Others), By End Product (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global viral vector and plasmid DNA manufacturing market press release, click the link below: https://www.coherentmarketinsights.com/press-release/viral-vector-and-plasmid-dna-manufacturing-market-to-surpass-us-17-billion-by-2026-399
Key players in the market are focused on adopting growth strategies such as mergers and acquisitions, collaborations, license agreements, and partnerships to expand their product portfolio and presence in the viral vector and plasmid DNA manufacturing market. For instance, in April 2018, Vigene Biosciences Inc. (Vigene), a biotechnology company for viral vector production and development, partnered with Virovek to utilize Vigene’s proprietary Adeno-associated Virus (AAV) Production Technology, where baculovirus (BAC) expression system is used for Adeno-associated Virus (AAV) production. Vectors produced from BAC-to-AAV technology can infect and transduce large number of mammalian cells in-vivo and in-vitro.
Moreover, in December 2017, Lonza, Massachusetts Eye and Ear (MEE), and Akouos, a biotechnology company, entered strategic license agreements to obtain exclusive rights to design adeno-associated viral vectors (Anc- AAV) gene therapy for hearing and balance disorder.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/962
Key Takeaways of the Global Viral Vector and Plasmid DNA Manufacturing Market:
- The global viral vector and plasmid DNA manufacturing market is expected to exhibit a CAGR of 22.8% over the forecast period, owing to rising incidence of cancer and infectious disease. For instance, according to the National Cancer Institute (NCI) estimation, in 2018, around 1,735,350 new cases of cancer were diagnosed in the U.S. Moreover, in November 2019, the Public Health England estimated that nearly 103,800 people were living with HIV in the UK in 2018.
- Among product type, the viral vector segment accounted for a significant market share in 2018, owing to increasing funding for research and development of efficient products to meet demand. For instance, in February 2018, Cobra Biologics and Symbiosis Pharmaceutical Services received a 16-month collaborative funding of US$ 2.5 Mn from Innovate UK. The fund is expected to assist Cobra Biologics and Symbiosis Pharmaceutical Services to increase their commercial viral vector manufacturing capabilities within the U.K.
- Among therapeutic application, the cancer segment accounted for significant market share in 2018. An increasing prevalence of cancer is expected to drive demand for gene therapies and create favorable opportunities for clinical-stage biopharmaceutical companies to develop and manufacture novel gene therapies. For instance, according to the Cancer Research UK estimation, around 363,484 new cases of cancer were diagnosed from 2014 to 2016 in the UK.
- Companies operating in the global viral vector and plasmid DNA manufacturing market include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics, and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
Other Related Reports:
About Us:Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.
Editor Details
-
Company:
- CDN Newswire
